Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Maurus

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 21, 2013
RNA-binding protein Hermes/RBPMS inversely affects synapse density and axon arbor formation in retinal ganglion cells in vivoHanna Hörnberg, Francis Wollerton-van Horck, Daniel Maurus, et al.
Science (New York, N.Y.)|January 30, 2021
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human seraAlexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
Nature|September 30, 2020
COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|January 20, 2021
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|May 27, 2021
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUgur Sahin, Alexander Muik, Isabel Vogler, et al.
Nature|July 16, 2025
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUğur Şahin, Alexander Muik, Isabel Vogler, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 21, 2013
RNA-binding protein Hermes/RBPMS inversely affects synapse density and axon arbor formation in retinal ganglion cells in vivoHanna Hörnberg, Francis Wollerton-van Horck, Daniel Maurus, et al.
Science (New York, N.Y.)|January 30, 2021
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human seraAlexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
Nature|September 30, 2020
COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|January 20, 2021
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responsesUgur Sahin, Alexander Muik, Evelyna Derhovanessian, et al.
Nature|May 27, 2021
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUgur Sahin, Alexander Muik, Isabel Vogler, et al.
Nature|July 16, 2025
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansUğur Şahin, Alexander Muik, Isabel Vogler, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Pageof 2